NL129025C
(fr)
*
|
1965-04-29 |
|
|
|
US3542729A
(en)
*
|
1968-03-19 |
1970-11-24 |
Sankyo Co |
Stabilization of synthetic polymers
|
BE790675A
(fr)
*
|
1971-10-29 |
1973-04-27 |
Science Union & Cie |
Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
|
US4244961A
(en)
*
|
1978-10-26 |
1981-01-13 |
Syntex (U.S.A.) Inc. |
1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
|
US4255432A
(en)
*
|
1979-09-06 |
1981-03-10 |
Syntex (U.S.A.) Inc. |
8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
|
ES8401072A1
(es)
*
|
1982-11-23 |
1983-12-16 |
Faes |
Procedimiento de preparacion de un nuevo espirodecano.
|
HU204054B
(en)
*
|
1989-08-10 |
1991-11-28 |
Richter Gedeon Vegyeszet |
Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
|
YU150489A
(sh)
*
|
1989-08-10 |
1992-12-21 |
W.L. Gore & Co. Gmbh. |
Uređaj za ispitivanje odevnih predmeta na nepromočivost
|
FR2666583B1
(fr)
*
|
1990-09-06 |
1994-09-09 |
Adir |
Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
|
FR2734265B1
(fr)
*
|
1995-05-17 |
1997-06-13 |
Adir |
Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
CA2434430A1
(fr)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
Utilisation de composes d'azetidinone substituee pour le traitement de la sitosterolemie
|
TW200840563A
(en)
*
|
2001-01-26 |
2008-10-16 |
Schering Corp |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
|
RS51449B
(sr)
*
|
2001-01-26 |
2011-04-30 |
Schering Corporation |
Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
US20030053981A1
(en)
*
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
NZ542090A
(en)
*
|
2001-01-26 |
2006-09-29 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
CZ20032031A3
(cs)
*
|
2001-01-26 |
2003-12-17 |
Schering Corporation |
Farmaceutický prostředek
|
US20030013699A1
(en)
*
|
2001-05-25 |
2003-01-16 |
Davis Harry R. |
Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
|
DE10130020A1
(de)
*
|
2001-06-25 |
2003-12-04 |
Gruenenthal Gmbh |
Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
|
DE10146275A1
(de)
|
2001-09-18 |
2003-04-24 |
Gruenenthal Gmbh |
Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
|
CN1556700A
(zh)
*
|
2001-09-21 |
2004-12-22 |
���鹫˾ |
使用甾醇吸收抑制剂治疗或预防脉管炎的方法
|
DE60216300T2
(de)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
ATE502635T1
(de)
|
2002-08-19 |
2011-04-15 |
Pfizer |
Kombinationstherapie gegen hyperproliferative erkrankungen
|
AU2003291719A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
DE602004018617D1
(de)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
JP5137228B2
(ja)
|
2003-03-07 |
2013-02-06 |
メルク・シャープ・アンド・ドーム・コーポレーション |
高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
|
CN1756755A
(zh)
*
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
WO2005046797A2
(fr)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
|
WO2005075484A2
(fr)
|
2004-02-10 |
2005-08-18 |
F. Hoffmann-La Roche Ag |
Modulateurs des recepteurs ccr5 de chimiokine
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
WO2008070496A2
(fr)
|
2006-12-01 |
2008-06-12 |
Bristol-Myers Squibb Company |
Inhibiteurs d'amino cetp étendus
|
CA2682639A1
(fr)
*
|
2007-03-29 |
2008-10-09 |
F. Hoffmann-La Roche Ag |
Composes heterocycliques antiviraux
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA2688161C
(fr)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN102766147B
(zh)
*
|
2012-08-03 |
2015-07-15 |
无锡药兴医药科技有限公司 |
一种芬司匹利及其氢卤酸盐的制备方法
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(fr)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
EP2986599A1
(fr)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
GB201416346D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
US11248001B2
(en)
|
2019-01-18 |
2022-02-15 |
Astrazeneca Ab |
PCSK9 inhibitors and methods of use thereof
|